专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08283359B2 Thieno-pyridine derivatives as MEK inhibitors 有权
标题翻译：噻吩并吡啶衍生物作为MEK抑制剂
公开(公告)号：US08283359B2
公开(公告)日：2012-10-09
申请号：US12182931
申请日：2008-07-30
申请人： Martin Clive Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
发明人： Martin Clive Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
IPC分类号： A61K31/44 , C07D513/02
CPC分类号： C07D495/04
摘要： A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
摘要翻译：一系列被取代的苯胺基部分在2位被取代的噻吩并[2,3-b]吡啶衍生物是人MEK（MAPKK）酶的选择性抑制剂，因此在医学中有益，例如在治疗中的炎症，自身免疫，心血管，增殖（包括肿瘤）和伤害感受条件。

2. 发明申请

US20100179185A1 Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof 审中-公开
标题翻译：新型氨基噻吩并吡啶酮衍生物制备方法及其药物组合物
公开(公告)号：US20100179185A1
公开(公告)日：2010-07-15
申请号：US12515380
申请日：2007-11-23
申请人： Jeremy Martin Davis , Daniel Christopher Brookings , Barry John Langham , Martin Clive Hutchings
发明人： Jeremy Martin Davis , Daniel Christopher Brookings , Barry John Langham , Martin Clive Hutchings
IPC分类号： A61K31/4365 , C07D495/04 , A61P29/00
CPC分类号： C07D495/04
摘要： The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
摘要翻译：本发明涉及式I的新型3-氨基噻吩并吡啶酮衍生物，其制备方法，含有它们的药物组合物及其作为药物的用途。

3. 发明授权

US08394822B2 Thieno-pyridine derivatives as MEK inhibitors 有权
标题翻译：噻吩并吡啶衍生物作为MEK抑制剂
公开(公告)号：US08394822B2
公开(公告)日：2013-03-12
申请号：US13604282
申请日：2012-09-05
申请人： Martin Clive Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
发明人： Martin Clive Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
IPC分类号： A61K31/44
CPC分类号： C07D495/04
摘要： A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
摘要翻译：一系列被取代的苯胺基部分在2位被取代的噻吩并[2,3-b]吡啶衍生物是人MEK（MAPKK）酶的选择性抑制剂，因此在医学中有益，例如在治疗中的炎症，自身免疫，心血管，增殖（包括肿瘤）和伤害感受条件。

4. 发明授权

US07456286B2 Bicyclic heteroaromatic compounds as kinase inhibitors 失效
标题翻译：双环杂芳族化合物作为激酶抑制剂
公开(公告)号：US07456286B2
公开(公告)日：2008-11-25
申请号：US10529413
申请日：2003-09-30
申请人： Daniel Christopher Brookings , Rachel Jane Cubbon , Jeremy Martin Davis , Barry John Langham
发明人： Daniel Christopher Brookings , Rachel Jane Cubbon , Jeremy Martin Davis , Barry John Langham
IPC分类号： C07D471/02 , A01N43/90
CPC分类号： C07D471/04
摘要： A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
摘要翻译：基于5-氧代-4,5-二氢-1H-吡咯并[3,2-b]吡啶环体系的一系列5-6稠环双环杂芳族衍生物是p38激酶的抑制剂，因此是用于医学中，例如用于治疗和/或预防免疫或炎性疾病。

5. 发明授权

US07592455B2 Bicyclic heteroaromatic compounds as kinase inhibitors 失效
标题翻译：双环杂芳族化合物作为激酶抑制剂
公开(公告)号：US07592455B2
公开(公告)日：2009-09-22
申请号：US10524199
申请日：2003-08-11
申请人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
发明人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
IPC分类号： C07D513/02
CPC分类号： C07D495/04
摘要： A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
摘要翻译：一系列基于6-氧代-6,7-二氢噻吩并[2,3-b]吡啶环体系的5-6稠环双环杂芳族衍生物是p38激酶的抑制剂，因此可用于医药，例如在治疗和/或预防免疫或炎性疾病中。

6. 发明授权

US07423047B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors 失效
标题翻译：芳胺取代的双环杂芳族化合物作为p38激酶抑制剂
公开(公告)号：US07423047B2
公开(公告)日：2008-09-09
申请号：US10518725
申请日：2003-06-20
申请人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
发明人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
IPC分类号： A61K31/4365
CPC分类号： C07D495/04
摘要： Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH═ group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
摘要翻译：描述了式（1）的双环杂芳族衍生物：F（1）其中：连接A和C（R a）的虚线表示键，A是-N-原子或或者虚线不存在，A是-N（R b） - 或-C（R b）（R c）） - 基团; X是-O-，-S-或取代的氮原子或-S（O） - ， - S（O）2 - 或-NH-基团; Y是氮或取代的碳原子或-CH-基团; n为零或整数1; Alk 1是任选取代的脂族或杂脂族链L 1是共价键或连接原子或基团; Cy 1是氢原子或任选取代的脂环族，多环脂族，杂脂环族，多杂环脂族，芳族或杂芳族基团; Ar是任选取代的芳族或杂芳族基团; 并且其余的取代基在说明书中定义。这些化合物是p38激酶的有效和选择性抑制剂，可用于预防和治疗免疫或炎症性疾病。

7. 发明申请

US20120329774A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS 有权
标题翻译：作为MEK抑制剂的三苯基吡啶衍生物
公开(公告)号：US20120329774A1
公开(公告)日：2012-12-27
申请号：US13604282
申请日：2012-09-05
申请人： Clive Martin Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
发明人： Clive Martin Hutchings , Sarah Catherine Archibald , Daniel Christopher Brookings , Jeremy Martin Davis , James Andrew Johnson , Barry John Langham , Judi Charlotte Neuss
IPC分类号： A61K31/4365 , A61K31/496 , A61K31/4545 , A61K31/551 , A61P35/02 , A61P29/00 , A61P9/00 , A61P35/00 , A61P25/00 , A61K31/5377 , A61P37/00
CPC分类号： C07D495/04
摘要： A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
摘要翻译：一系列被取代的苯胺基部分在2位被取代的噻吩并[2,3-b]吡啶衍生物是人MEK（MAPKK）酶的选择性抑制剂，因此在医学中有益，例如在治疗中的炎症，自身免疫，心血管，增殖（包括肿瘤）和伤害感受条件。

8. 发明授权

US07521460B2 Thienopyridone derivatives as kinase inhibitors 失效
标题翻译：噻吩并吡喃酮衍生物作为激酶抑制剂
公开(公告)号：US07521460B2
公开(公告)日：2009-04-21
申请号：US10561052
申请日：2004-06-18
申请人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
发明人： Daniel Christopher Brookings , Jeremy Martin Davis , Barry John Langham
IPC分类号： A01N43/42 , A61K31/44 , C07D513/02 , C07D515/02
CPC分类号： C07D495/04
摘要： A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
摘要翻译：在2-位被羰基或磺酰基连接的吡咯烷-1-基或相关部分取代的一系列噻吩并[2,3-b]吡啶-6（7H） - 酮衍生物，是p38MAP激酶的抑制剂因此在药物中使用，例如用于治疗和/或预防免疫或炎症性疾病。

9. 发明授权

US07323464B2 Pyridine and pyrimidine derivatives 失效
标题翻译：吡啶和嘧啶衍生物
公开(公告)号：US07323464B2
公开(公告)日：2008-01-29
申请号：US10495885
申请日：2002-11-20
申请人： Jeremy Martin Davis , Barry John Langham , Manisha Naik , Daniel Christopher Brookings , Rachel Jane Cubbon , Richard Jeremy Franklin
发明人： Jeremy Martin Davis , Barry John Langham , Manisha Naik , Daniel Christopher Brookings , Rachel Jane Cubbon , Richard Jeremy Franklin
IPC分类号： C07D403/04 , A61K31/506
CPC分类号： C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14
摘要： Compounds of formula (1) are described in which Ra and Rb is each independently a hydrogen atom or a group Rc, or Ra and Rb together form an oxo (═O) or thio (═S) group; X is a N atom or an optionally substituted CH group: Y is a —O— or —S— atom or —SO— or —SO2— group or an optionally substituted —CH2— or —NH— group with the proviso that when Ra and Rb together form an oxo (═O) or thio (═S) group Y is an optionally substituted —CH2— or —NH-group; L1 is a covalent bond or a linker atom or group; p is zero or the integer 1; Alk1 is an optionally substituted C1-10aliphatic or C1-10heteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted —CH2— group; Ar is an optionally substituted C6-12aromatic or C1-9heteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R1, Rc and Rd are hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of p38 kinase and are useful in the treatment of immune or inflammatory disorders.
摘要翻译：描述式（1）的化合物，其中R a和R b各自独立地为氢原子或基团R c，或R （-O）或硫代（-S）基团一起形成一个或多个， X是N原子或任选取代的CH基团：Y是-O-或-S-原子或-SO-或-SO 2 - 基团或任选取代的-CH 2 或-NH-基团，条件是当R a a和R b一起形成氧代（-O）或硫代（-S）基团Y 是任选取代的-CH 2 - 或-NH-基团; L 1是共价键或连接子原子或基团; p为零或整数1; Alk 1是任选取代的C 1-10 1-10脂族或C 1-10 1-10杂脂肪族链; n为整数1,2或3，条件是当n为零时，Y为任选取代的-CH 2 - 基团; Ar是任选取代的C 6-12芳族或C 1-19杂芳族基团; m为零或整数1,2或3; q为零或整数1或2; R 1，R 2和R d是氢原子或专利说明书中所述的取代基; 及其盐，溶剂合物，水合物和N-氧化物。这些化合物是p38激酶的有效和选择性抑制剂，可用于治疗免疫或炎症性疾病。

10. 发明授权

US07176215B2 Bicyclic oxopyridine and oxopyrimidine derivatives 失效
标题翻译：双环氧基吡啶和氧代嘧啶衍生物
公开(公告)号：US07176215B2
公开(公告)日：2007-02-13
申请号：US10492466
申请日：2002-10-16
申请人： Jeremy Martin Davis , Daniel Christopher Brookings , Barry John Langham
发明人： Jeremy Martin Davis , Daniel Christopher Brookings , Barry John Langham
IPC分类号： A01N43/42 , A61K31/44 , C07D471/02 , C07D491/02 , C07D498/02
CPC分类号： C07D471/04 , C07D495/04
摘要： Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a —N═ atom or a —N(Rb)—, —C(Rb)═ or —C(Rb)(RC)— group; Ra, Rb and Rc is each independently a hydrogen atom or an optionally substituted C1-6alkyl group; X is an —O— or —S— atom or —NH— group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis
摘要翻译：描述式（1a）和（1b）的化合物：其中虚线表示任选的键; A是-N-原子或-N（R b） - ， - C（R b） - 或-C（R b） >）（R 0 C） - 基团; R a，R b和R c各自独立地为氢原子或任选取代的C 1-6烷基，烷基; X是-O-或-S-原子或-NH-基团或取代的N原子; 每个Y独立地是N原子或CH基团或取代的C原子; n为零或整数1; Alk 1是任选取代的脂族或杂脂族链L 1是共价键或连接原子或基团; Cy 1是氢原子或任选取代的脂环族，多环脂族，杂脂环族，多杂环脂族，芳族或杂芳族基团; Ar是任选取代的芳族或杂芳族基团; 及其盐，溶剂合物，水合物及其N-氧化物; 这些化合物是p38激酶的有效抑制剂，并且用于预防或治疗p38激酶介导的疾病或病症，例如类风湿性关节炎

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式